NEW YORK (GenomeWeb News) — The Montreal Heart Institute has been awarded a CAN$5 million ($5.1 million) grant to fund a research project based on its academic and private partnerships in pharmacogenomics, MHI said late last week.
The funding was awarded as part of a Genome Quebec competition aimed at fostering public and private participation in developing personalized medical technologies.
As GenomeWeb Daily News reported last week, MHI will partner with VIA Pharmaceuticals to perform genomics and proteomics studies and to develop a genotyping panel that the company could use in Phase II clinical trials for an acute coronary syndrome drug.